Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39094070.
- Also identified by DOI 10.1200/OP-24-00501 and PMC identifier 11787399.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Time and other considerations when evaluating a switch to newer drug formulations (eg, subQ vs IV).
Medical subject headings
- Antineoplastic Agents
- Neoplasms